Friday, 26 Sep 2025
  • About Us
  • Contact Us
  • Terms and Conditions
  • Privacy Policy
Subscribe
Life Care News
  • Home
  • Business
    • Business Wire
    • Globenews Wire
  • News
    NewsShow More
    बिग बॉस 19 एपिसोड 32: जबरदस्त टकराव, टूटी दोस्तियां और चौंकाने वाला मोड़!
    बिग बॉस 19 एपिसोड 32: जबरदस्त टकराव, टूटी दोस्तियां और चौंकाने वाला मोड़!
    25/09/2025
    Bigg Boss 19 Episode 32: Explosive Clashes, Broken Friendships and a Shocking Twist!
    Bigg Boss 19 Episode 32: Explosive Clashes, Broken Friendships and a Shocking Twist!
    25/09/2025
    Abu Dhabi Autonomous Summit to define the future of smart mobility as part of Abu Dhabi Autonomous Week 2025
    Abu Dhabi Autonomous Summit to define the future of smart mobility as part of Abu Dhabi Autonomous Week 2025
    25/09/2025
    VESTIAIRE COLLECTIVE RELEASES FIRST MENSWEAR RESALE REPORT AS PART OF ITS MEN’S CATEGORY LAUNCH
    VESTIAIRE COLLECTIVE RELEASES FIRST MENSWEAR RESALE REPORT AS PART OF ITS MEN’S CATEGORY LAUNCH
    25/09/2025
    Bigg Boss 19 Review Explosive Fights, Shocking Nominations & Abhishek’s Captaincy | Episode Analysis
    Bigg Boss 19 Review Explosive Fights, Shocking Nominations & Abhishek’s Captaincy | Episode Analysis
    25/09/2025
  • Tech
  • Health
  • Sports
  • Entertainment
  • Automobile
  • 🔥
  • news
  • global
  • Business
  • june
  • today
  • announced
  • july
  •  and
  •  the
  • Tech
Font ResizerAa
Life Care NewsLife Care News
  • Home
  • Business
  • News
  • Tech
  • Health
  • Sports
  • Entertainment
  • Automobile
Search
  • Home
  • Business
    • Business Wire
    • Globenews Wire
  • News
  • Tech
  • Health
  • Sports
  • Entertainment
  • Automobile
Follow US
© 2022 Foxiz News Network. Ruby Design Company. All Rights Reserved.
Health

GlucoModicum Reports Positive Clinical Results with its Needle-Free CGM and Advances Toward Market Launch

GlobeNews Wire
Last updated: 02/07/2025 4:19 PM
GlobeNews Wire
Share
5 Min Read
GlucoModicum Reports Positive Clinical Results with its Needle-Free CGM and Advances Toward Market Launch
SHARE
GlucoModicum Reports Positive Clinical Results with its Needle-Free CGM and Advances Toward Market Launch

GlucoModicum Reports Positive Clinical Results with its Needle-Free CGM and Advances Toward Market Launch

  • Comprehensive clinical performance study encompassed 646 participant visits, including both Type 2 diabetic patients and healthy volunteers
  • Magnetohydrodynamic (MHD) technology achieves 11.5% MARD in extensive clinical performance study using mass-manufactured devices, validating commercial-scale production capability

Helsinki, Finland – July 2, 2025 — GlucoModicum, a health technology innovator focused on needle-free glucose monitoring, today announced positive results from its Clinical Performance Study (CPS), marking a milestone in the development of its needle-free continuous glucose monitor (CGM), placing the Company on a clear path to commercialization.

High clinical accuracy achieved, in a commercial-scale product

In Q1 2025, GlucoModicum completed a large Clinical Performance Study in accordance with the European Union In Vitro Diagnostic Regulation (IVDR). The study involved 646 participant visits, including both individuals with type 2 diabetes and healthy volunteers, representing one of the largest clinical evaluations of its kind in the continuous glucose monitoring (CGM) industry.

Participants in the study used GlucoModicum’s next-generation, needle-free CGM across both standard multi-hour glucose tolerance tests and ambulatory conditions involving exercise and meals. All the sensors used in the study were produced using GlucoModicum’s proprietary mass-manufacturing blueprint.

The study demonstrated a Mean Absolute Relative Difference (MARD) of 11.5%*, approaching the industry benchmark of 10% set by leading needle-based CGM systems. The full study results (ID: 2023/00915/FIMEA/K485) will be reported to Finland’s medicines agency, FIMEA, as a part of the regulatory process, anticipated in 2H 2025.

Jokke Mäki, CEO of GlucoModicum commented: “GlucoModicum has solved the technical and manufacturing challenges that have long held back needle-free CGMs and done so at low cost, putting us at the forefront of the field and within reach of delivering the world’s first truly needle-free continuous glucose monitoring solution.

“To the best of our knowledge, no other needle-free technology designed for use in the general diabetic population has passed beyond early lab-stage concepts (TRL 3), GlucoModicum is entering TRL 8 – the final stage before market launch**. We believe our technology has enormous potential to make continuous glucose monitoring accessible to millions more people worldwide.”

Key Regulatory Milestones Reached ahead of CE Marking

These positive results from the clinical studies follow key regulatory milestones GlucoModicum has achieved:

  • In Q1 2025, GlucoModicum successfully completed an ISO 13485 audit conducted by Eurofins Electric & Electronics Finland, which is designated by European Commission as a Notified Body according to the Medical Device Regulation (MDR). The audit concluded with zero non-conformities and zero deviations, establishing a strong foundation for the final stages of the regulatory approval process. This Notified Body is expected to oversee GlucoModicum’s CE marking process.
  • In Q2 2025 Finland’s medicines agency, FIMEA, granted GlucoModicum authorization to initiate a new clinical investigation under Article 62 of the EU MDR (2017/745), enabling GlucoModicum to generate clinical data about the device’s safety and performance as required for CE marking and market entry.

MARD (Mean Absolute Relative Difference) measures the average difference between a device measurement (or test result) and the reference measurement at normal to high glucose levels. The lower the MARD, the better the agreement between the device and the reference/comparator measurement. A MARD of 10% is considered excellent for current needle-based systems.

*The study tested different variations of the system as a part of the optimization process. The achieved 11.5% MARD corresponds to the best performing system using one-point calibration (n=208). GlucoModicum’s first product is intended to be calibration free.

**TRL (Technology Readiness Level) is a standardized scale used to measure the maturity of a technology as it progresses from concept to commercialization. (https://medicalcountermeasures.gov/trl/trls-for-medical-devices)

– END –

Media Contacts

ICR Healthcare

Chris Welsh / Evi Useh

Email: glucomodicum@ICRHealthcare.com

About GlucoModicum

GlucoModicum Ltd is a Finnish health tech company pioneering needle-free health monitoring solutions, with its first product developed for glucose monitoring.

The company is committed to transforming diabetes care through innovative sensor technology — making glucose monitoring more accessible for people with diabetes and pre-diabetes, as well as scalable and cost-effective for healthcare providers and payors.

Our vision: Empower over one billion people to live healthier lives

Press Release: Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology
China National Building Material Group Successfully Hosts Indonesia Promotion Conference and Innovation Achievements Exhibition in Jakarta
SO TECHAFRICA and Mindhyve.ai Forge Strategic Alliance to Advance Agentic AI for National Development in Nigeria
LA28 builds momentum through local and national cooperation
SEON Launches AI-Powered Anti-Money Laundering Suite, Enhancing its Comprehensive Command Center for Risk Management
TAGGED: and withadvancesannouncedcgmclinicalcontinuouscpsdevelopmentfinlandfocusedglucomodicumglucoseHealthhelsinkiinnovatorits julylaunchmarketmarkingmilestonemonitormonitoringneedle-freeneedlefreenewsperformancepositivereportsresultsstudyTechnologytodaytoward
Share This Article
Facebook Copy Link Print
- Advertisement -

Your Trusted Source for Accurate and Timely Updates!

Our commitment to accuracy, impartiality, and delivering breaking news as it happens has earned us the trust of a vast audience. Stay ahead with real-time updates on the latest events, trends.
FacebookLike
XFollow
PinterestPin
InstagramFollow
YoutubeSubscribe
LinkedInFollow
MediumFollow

Most Selling Products

Top Picks, Trending Now – Discover the Best Sellers!
Tecno Camon 20 Premier 5G

Tecno Camon 20 Premier 5G

Dark Welkin | 8GB RAM + 512GB Storage (Expandable RAM up to 16GB) | Industry’s 1st 50MP RGBW-Pro Camera | Segment-First 108MP Ultra-Wide Macro Lens | 6.67" 120Hz 10-bit AMOLED In-Display

iQOO Z10 Lite 5G

iQOO Z10 Lite 5G

Titanium Blue | 6GB RAM + 128GB Storage | Dimensity 6300 5G with 433K+ AnTuTu Score | Robust 6000mAh Battery | IP64 Rated + Military-Grade Shock Resistance

OnePlus 13s

OnePlus 13s

Black Velvet | 12GB RAM + 256GB Storage | Flagship Snapdragon® 8 Elite Chipset | Exceptional Battery Life in a Compact Form | Lifetime Display Warranty Included

Samsung Galaxy A55 5G

Samsung Galaxy A55 5G

Awesome Iceblue | 8GB RAM + 256GB Storage | Premium Metal Frame | 50MP OIS Main Camera with Nightography | IP67 Water & Dust Resistance | Gorilla Glass Victus+ | sAMOLED Display with Vision Booster

You Might Also Like

Titomic Celebrates Grand Opening of New European Facility in Heerenveen, Netherlands
Automobile

Titomic Celebrates Grand Opening of New European Facility in Heerenveen, Netherlands

24/09/2025
Sanas Receives Frost & Sullivan’s 2025 North American Company of the Year Recognition for Leadership in Accent Translation Solutions
Entertainment

Sanas Receives Frost & Sullivan’s 2025 North American Company of the Year Recognition for Leadership in Accent Translation Solutions

07/09/2025
Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial
Business

Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial

31/08/2025
Novo Nordisks subcutaneous and oral amycretin data published in The Lancet and presented at ADA 2025
Health

Novo Nordisks subcutaneous and oral amycretin data published in The Lancet and presented at ADA 2025

21/06/2025
Life Care News
Facebook Twitter Youtube Rss Medium

Life Care News:


We increase the awareness of millions of users through our news networks. We are one of the most trusted news networks in the world.

Top Categories
  • Home
  • Business
  • News
  • Tech
  • Health
  • Sports
  • Entertainment
  • Automobile
Usefull Links
  • About Us
  • Contact Us
  • Terms and Conditions
  • Privacy Policy
Copyright © 2015 – 2025 LifeCareNews Network. All Rights Reserved. LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283
Life Care NewsLife Care News
Copyright © 2015 - 2025 LifeCareNews Network. All Rights Reserved. LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?